The First Affiliated Hospital with Nanjing Medical University: Lymphoma trials

The registry lists 26 Lymphoma studies with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 10Phase 3 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.Not yet recruitingNCT06953739Phase 3
• Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular SubtypesRecruitingNCT06891157Phase 2
• A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
• Chi-GVM Regimen for the Treatment of R/R PTCLRecruitingNCT06211881Not applicable
• The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.RecruitingNCT05931328Phase 2
• CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaRecruitingNCT05896813Not applicable
• The Whole-course Management of Pegaspargase in ENKTLNot yet recruitingNCT05426824Not applicable
• Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingNCT05347641Phase 2
• A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell LymphomaNot yet recruitingNCT05343377Not applicable
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
• R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
• R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
• Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell LymphomaStatus unknownNCT05774028Phase 2
• Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)Status unknownNCT05772728Not applicable
• A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
• Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
• A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04356846Phase 1
• LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 1
• Study of LUCAR-20S in Patients With R/R NHLTerminatedNCT04176913Phase 1
• Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeStatus unknownNCT04094051
• CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaStatus unknownNCT04026100Phase 1
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
• Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
• Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Phase 2
• Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT02767674Phase 3
• Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.Status unknownNCT01670370Phase 2